drugset / Trial / NCT04298372
Frontline Lenalidomide for AL Amyloidosis Involving Myocardium
NaSingle-groupOpen-labelTreatment
Summary
This phase II clinical trial aimed at influencing the improvement of major organ functions, especially the objective response rate, in Amyloid light-chain amyloidosis involving myocardium.
Timeline
- Start
- 2019-02-20
- Primary completion
- 2021-11-25
- Completion
- 2021-11-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 25 mg | Oral |
| Background | Dexamethasone | Small molecule | 20 mg | Oral |
| Background | Dexamethasone | Small molecule | 40 mg | Oral |